Obstetrics & Gynecology Doctors in Moorhead, MN Accepting Medicare

1 Obstetrics & Gynecology doctors found. Showing 1 - 1

Donald R. Gullicks, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4000 28th Ave S, Moorhead, MN 56560 Phone: 701-234-3200    Fax: 701-234-3239

News Archive

Medications to treat arrhythmias may increase the risk of developing cancer

One of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug.

iCAD, Hitachi enter distribution agreement for MRI breast cancer diagnosis and guided biopsy solution

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that it has entered into a distribution agreement with Hitachi Medical Systems.

Drug-resistant tuberculosis levels described as alarming by international study

A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

NanoString announces Early Access Program for nCounter Elements used in translational research

NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an Early Access Program for nCounter Elements™, a line of General Purpose Reagents (GPRs) developed specifically to meet the needs of translational research and clinical laboratories.

Read more Medical News

› Verified 2 days ago